Quest Diagnostics has introduced a new blood test aimed at assisting physicians in confirming amyloid brain pathology related ...

Quest Diagnostics introduces AD-Detect Abeta, a new laboratory blood test, to detect Alzheimer's disease without any PET imaging and cerebral spinal fluid testing.

The beta amyloid peptide (Abeta) is the primary component of the senile plaques observed in the brains of Alzheimer's patients, and this peptide is toxic to neurons and other cells in many different ...

The laboratory-developed test, named AD-Detect™ Abeta 42/40 and p-tau217 Evaluation ... as well as p-tau181 and the ApoE isoform, a genetic risk marker. Those tests help providers assess ...

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer's disease (early AD) wh ...

The AD-Detect Abeta combines results of blood levels of ... greater than 90% sensitivity and accuracy due to the addition of ApoE, a genetic risk marker. The blood test fulfills acceptable ...